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No IFD Proven or Probable IFD
MBL>1000 79 (84.9%) 14 (15.1%)
MBL<1000 52 (88.1%) 7 (11.9%)
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patients enrolled in a previous prospective cohort study.
Serum samples from 152 patients with hematologic malig-
nancies who received chemotherapy and/or HSCT between
December 2001 and November 2006 were collected before
or early after treatment initiation and stored at -70oC.
Quantiﬁcation of MBL levels was performed by a sandwich-
ELISA assay (Viracor-IBT laboratories, Mo). Patients were
followed for 6 months and scored as developing proven or
probable IFD or not. The relationship between MBL level and
developing proven or probable IFD was assessed using chi-
square and Mann-Whitney tests. Survival analyses including
logistic regression and Cox Proportional Hazards models
were used to test the effect of MBL level and IFD status on
overall survival and whether MBL level has an effect on IFD-
free survival time.
Results: Forty-ﬁve of 152 patients (29.6%) developed IFD
during the 6 months follow-up period of which 21 (46.7% of
IFD cases and 13.8% of patients) were proven or probable IFD.
Fifty-nine of 152 patients (38.8%) hadMBL levels below 1,000
ng/ml. The rates of proven or probable IFD in patients with
MBL levels belowand above 1,000 ng/mLwere 11.9% and 15.1
% respectively (P¼.579). Mean MBL levels were lower in the
IFD-free group (2085 vs 2398, p¼.429). MBL levels below
1,000 ng/ml were not a predictor of death (P¼.233). Mean
IFD- free survival times in patients with MBL levels below
and above 1,000 ng/ml were 20 weeks and 21 weeks
respectively (P¼.423). As expected, proven or probable IFD
was associated with death (P<.0001).
Conclusions: Our ﬁndings indicate that lowMBL levels were
not associatedwith an increased risk of developing proven or
probable IFD or overall survival in patients with hematologic
malignancy.
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Background: In relapsed or refractory AML allogeneic
transplantation (HCT) is considered to be the only chance to
achieve long-term survival but still only about 40% of
younger patients receive allogeneic HCT. Moderate activity of
salvage regimens and accumulating toxicity of chemo-
therapy are reasons that may prevent from transplantation.
Our goal was to study the safety and efﬁcacy of a clofarabine
salvage therapy prior to allogeneic HCT. Here, we report data
from patients of stage I of a two-stage phase II study.
Patients and Methods: Patients above the age of 40 with
relapsed or refractory AML who were ﬁt for allogeneic HCT
were eligible to participate in this multicenter, single-arm
study. All patients received at least one cycle of clofarabine40 mg/m2 followed by intermediate dose cytarabine 1 g/m2
days 1-5 (CLARA). Patients with a donor who exposed at least
a reduction of leukemic blasts were scheduled for allogeneic
HCT in aplasia after CLARA. The conditioning regimen con-
sisted of clofarabine 30 mg/m2 on days -6 to -3 and
melphalan 140 mg/m2 on day -2. Cyclosporine in combina-
tion with MMF was used for GvHD prophylaxis. In patients
with partially matched unrelated donors the administration
of ATG was recommended. Primary endpoint was treatment
success deﬁned as a complete remission (CR, CR(i)) six weeks
after completion of therapy.
Results: Twenty-six patients were enrolled into stage I of
this trial. Median age was 60 years. Fifty percent of the
patients each had refractory or relapsed AML. At early
response assessment on day 15 after CLARA-1 13 patients
(50%) had less than 10% marrow blasts. Ten patients (38%)
showed a reduction in marrow cellularity or blast
percentage. Two patients did not have a signiﬁcant marrow
blast reduction. One patient died after the ﬁrst cycle CLARA
from septic multi-organ failure. Twenty-two patients (85%)
received allogeneic HCT within this trial. Donors were HLA-
identical siblings in 5 patients (23%), HLA-compatible unre-
lated donors in 11 patients (50%) and unrelated donors with
onemismatch in 6 patients (27%). Liver toxicity was themost
frequent adverse event. Seventeen patients (65%) developed
grade III liver enzyme elevationwhile Grade IV was observed
in 1 patient. Grad III/IV GvHD occurred in 6 patients (27%). All
26 patients have been evaluated for the primary endpoint.
Sixteen patients had a CR (62%) and 6 patients a CRi (23%) at
ﬁnal response evaluation.
With amaximum follow up of 19months 16 patients have
died (7 patients died after relapse). At present 10 patients are
alive, 6 of them had refractory disease.
Conclusion: Salvage therapy with CLARA and subsequent
conditioning with clofarabine and melphalan prior to allo-
geneic HCT provides good anti-leukemic activity in patients
with relapsed or refractory AML. The CR rate of the ﬁrst 26
patients was evaluated favorably and the trial is currently
recruiting into stage 2.231
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Background: Good risk AML patients (core binding factor
AML; diploid cytogenetics AML without Flt-3 ITD) are
frequently consolidated with 3-4 cycles of high dose cytar-
abine (HIDAC) after induction of remission. About 50% of
these patients relapse resulting in long term survival of 40-
60% (Marcucci et al. JCO vol. 23 :5705-5717; 2005).
Materials and Methods: We retrospectively analyzed the
outcomes of patients with good risk AML who underwent
ASCT since 2009.
Results: 17 patients (10 males; 7 females) were identiﬁed in
the database. Their median age was 60 years (range 29-80).
All patients had received HIDAC based induction followed by
at least one cycle of HIDAC based consolidation. Mobilizing
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Etoposide(15-40mg/kg) in 16 patients and growth factor
alone in one patient. Median time from diagnosis to ASCT
was 4.2 (range 3.6-7) months. Preparative regimen for ASCT
was Busulfan (3.2mg/kg x 4)/Etoposide (60 mg/kg) in 12
patients and high dose melphalan in 5 patients. The median
CD34 cells infused was 4.9 x 10e6/kg (range 2.8 to 15.9).All
patients engrafted with a median time to neutrophil
engraftment of 11 (range10-12) days. The median time to
platelet engraftment was 20 (range15-40) days. The median
length of inpatient stay during the ASCT admission was 14
(range 10-25) days. One patient died of progressive disease
14 months post ASCT. Two patients died in remission on day
53 (sepsis) and day 836 (unknown cause) post ASCT. Four-
teen patients (82%) are currently alive in complete remission.
at a median follow-up of 20 (range 1- 40) months post ASCT.
Conclusion: Consolidation of good risk AML patients with
ASCT following induction of complete remission is safe and
effective in preventing relapse in good risk AML patients.232
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In many cases the only curative treatment option for
patients with advanced leukemias may be hematopoietic cell
transplantation (HCT), which is often associated with toxic-
ities. Despite HCT, patients still relapse while others will not
have the option of HCT due to the unavailability of an HLA-
matched donor. We aim to overcome these hurdles using
anti-CD45 pretargeted radioimmunotherapy (PRIT) in lieu of
total body irradiation (TBI) for haploidentical bone marrow
transplantation (BMT). B6SJLF1/J mice were given 105
syngeneic myeloid leukemia cells followed by injection of
anti-CD45 antibody (30F11; 140 mg) conjugated to strepta-
vidin (SAv). Eight hours later a biotinylated synthetic clearing
agent (CA) (50 mg) was injected, followed by 90Y-labeled
DOTA- (2 mg) 2 hours later. This strategy resulted in excellent
localization of radioactivity in spleen [38.1  7.3 percent of
the injected dose of radioactivity per gram of organ (% ID/g)]
and bonemarrow (BM; 3.41.1% ID/g), withminimal uptake
in non-target organs (kidneys, 0.70 0.13% ID/g; lungs, 0.3
0.1% ID/g) 24 hours after radiobiotin injection. In separate
BMT studies, mice were treated with and without ﬂudar-
abine (FLU) (100 mg/kg/day) on days -8 to -4, and/or cyclo-
phosphamide (CY; 200 mg/kg/day) on days -2 and +2, and
30F11-SAv (140 mg) followed by CA (50 mg) and 400-800 mCi
of 90Y-DOTA-biotin three days prior to infusion of 15x106 BM
cells from haploidentical donor mice (CB6F1/J, H-2Dd). In
mice transplanted without TBI but using 800 mCi of 90Y-
DOTA-biotin, day 28 ﬂow cytometry analysis detected up to
12% donor CD8+ cells, with no reduction in levels ofchimerism in the absence of FLU or CY. Subsequently, mice
with disseminated syngeneic leukemia treated with the PRIT
approach in the absence of FLU and TBI showed an
improvement inmedian survival (OS) compared to untreated
leukemic mice (see FIGURE). Mice treated with 400-800 mCi
of 90Y-DOTA-biotin had a median OS of at least 50 days
compared to a median OS of 23 days in untreated control
mice. Forty percent of mice given 800 mCi of 90Y-DOTA-biotin
died early from complications from BM aplasia. These results
suggest that anti-CD45 PRIT can localize radiation effectively
to BM and spleen, and when used in conjunction with hap-
loidentical BMT without TBI or FLU, can facilitate engraft-
ment and lead to improvements in OS in a disseminated
murine leukemia model.
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Allogeneic hematopoietic stem-cell transplantation
(HSCT) from HLA identical sibling donors is standard of care
for children with high-risk acute lymphoblastic leukemia
